Related Experiment Video

Updated: Jul 11, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma

Ludivine Leseux1, Guy Laurent, Camille Laurent

  • 1INSERM, Unite 563, Centre de Physiopathologie de Toulouse Purpan, Université Toulouse III Paul-Sabatier, Toulouse, France.

Blood
|September 15, 2007
PubMed

Insights

This study reveals protein kinase C zeta (PKCzeta) is upregulated in follicular lymphoma, driving abnormal signaling. Rituximab targets this PKCzeta/MAPK/mTOR pathway, offering a new therapeutic strategy for follicular lymphoma.

Area of Science:

  • Oncology
  • Cellular Signaling
  • Immunotherapy

Background:

  • Rituximab's antitumor effects in malignant B cells involve complex signaling networks.
  • The specific role of protein kinase C zeta (PKCzeta), an atypical isoform, in rituximab response remains under investigation.

Purpose of the Study:

  • To investigate the role of PKCzeta in the cellular response to rituximab in follicular lymphoma.
  • To elucidate the regulatory mechanisms involving PKCzeta, MAPK, and mTOR pathways in follicular lymphoma.

Main Methods:

  • Compared PKCzeta expression and activity in follicular lymphoma cells versus nonmalignant B cells.
  • Assessed PKCzeta's regulation of the MAPK module and its impact on mTOR signaling.
  • Investigated rituximab's effect on the PKCzeta/MAPK/mTOR module in various B-cell lymphomas.
  • Examined the effect of constitutively active PKCzeta on rituximab sensitivity.

Main Results:

  • Follicular lymphoma cells showed increased PKCzeta expression and activity compared to nonmalignant B cells.
  • PKCzeta was identified as a critical regulator of the MAPK module, stimulating Raf-1 kinase activity.
  • PKCzeta significantly contributed to abnormal mTOR regulation in follicular lymphoma via a MAPK-dependent mechanism.
  • Rituximab inhibited the PKCzeta/MAPK/mTOR module specifically in follicular lymphoma cells.
  • Constitutively active PKCzeta conferred protection against rituximab in these cells.

Conclusions:

  • PKCzeta is a novel regulatory component of the mTOR pathway in follicular lymphoma.
  • PKCzeta is a key target of rituximab action in follicular lymphoma.
  • PKCzeta levels may predict rituximab efficacy and represent a promising target for follicular lymphoma therapy.

More Related Videos

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation07:17

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...